{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:36:03Z","timestamp":1784896563327,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2014.09.007","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T05:33:43Z","timestamp":1412055223000},"page":"314-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future"],"prefix":"10.1016","volume":"15","author":[{"given":"Anjali Varma","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"El-Bakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Abdul-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.09.007_bib1","unstructured":"National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/leuks.html. Accessed April\u00a02014."},{"key":"10.1016\/j.clml.2014.09.007_bib2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A\u00a0new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.09.007_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib4","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-13-0226","article-title":"Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia\u2013focus on the B-cell receptor","volume":"20","author":"Ten Hacken","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.09.007_bib6","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib7","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2009-05-219634","article-title":"In\u00a0vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia","volume":"114","author":"Calissano","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib8","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1182\/blood-2005-04-1718","article-title":"ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)","volume":"107","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib9","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2007-05-092486","article-title":"Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia","volume":"111","author":"Gattei","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib11","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ni735","article-title":"B\u00a0cells and professional APCs recruit regulatory T cells via CCL4","volume":"2","author":"Bystry","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2014.09.007_bib13","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2014.09.007_bib14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.2013.098459","article-title":"Chemotherapy induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia","volume":"99","author":"Gassner","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.09.007_bib16","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib17","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"1 suppl 2","key":"10.1016\/j.clml.2014.09.007_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/sonc.2003.50023","article-title":"First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin lymphoma","volume":"30","author":"Hainsworth","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib21","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib22","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.09.007_bib23","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib24","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.526.526","volume":"122","author":"Eichhorst","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2014.09.007_bib27","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib28","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.007_bib29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.007_bib30","doi-asserted-by":"crossref","first-page":"e83830","DOI":"10.1371\/journal.pone.0083830","article-title":"The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells","volume":"8","author":"Fiorcari","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2014.09.007_bib31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"},{"key":"10.1016\/j.clml.2014.09.007_bib32","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1200\/jco.2013.31.15_suppl.7070","article-title":"Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with relapsed\/refractory CLL (abstract)","volume":"31","author":"Patel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib33","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.1074\/jbc.274.43.30644","article-title":"Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt","volume":"274","author":"Craxton","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2014.09.007_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2172-2-4","article-title":"A\u00a0conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells","volume":"2","author":"Tomlinson","year":"2001","journal-title":"BMC Immunol"},{"key":"10.1016\/j.clml.2014.09.007_bib35","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","article-title":"Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement","volume":"191","author":"Petro","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2014.09.007_bib36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2014.09.007_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.09.007_bib38","doi-asserted-by":"crossref","unstructured":"Herman SE, Niemann CU, Farooqui M, et\u00a0al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia, Published online May 6, 2014; doi: 10.1038\/leu.2014.","DOI":"10.1038\/leu.2014.122"},{"key":"10.1016\/j.clml.2014.09.007_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/asheducation-2013.1.138","article-title":"Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies","volume":"2013","author":"Hallek","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.09.007_bib40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.09.007_bib42","first-page":"115","article-title":"Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed\/refractory (RR) chronic lymphocytic leukemia (CLL) (abstract 057)","volume":"31","author":"Seymour","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.528.528","article-title":"Ofatumumab\u00a0+ chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (abstract 528)","volume":"122","author":"Hillmen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in\u00a0vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells","volume":"152","author":"Patz","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.09.007_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.884.884","article-title":"Phase I study of RO5072759 (GA101) in relapsed\/refractory chronic lymphocytic leukemia (abstract 884)","volume":"114","author":"Morschhauser","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib46","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/leu.2012.252","article-title":"Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in","volume":"27","author":"Goede","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.09.007_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7004","volume":"31","author":"Goede","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib48","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","article-title":"Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib49","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib50","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib51","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","article-title":"Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease","volume":"27","author":"Lin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib52","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2014.09.007_bib53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1479-5876-11-259","article-title":"A\u00a0first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies","volume":"11","author":"Nemunaitis","year":"2013","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.clml.2014.09.007_bib54","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/leu.2012.144","article-title":"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells","volume":"26","author":"Johnson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.09.007_bib55","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib56","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib57","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.09.007_bib58","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11899-012-0145-y","article-title":"CARs in chronic\u00a0lymphocytic leukemia \u2013 ready to drive","volume":"8","author":"Hosing","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2014.09.007_bib60","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 co-stimulation provided through a CD19-specific chimeric antigen receptor enhances in\u00a0vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2014.09.007_bib61","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2014.09.007_bib62","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.09.007_bib63","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014004170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:12Z","timestamp":1761870372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014004170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S2152265014004170"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}